Clinical trial
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals…
NCT00332566 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00332566 |
|---|---|
| Title | Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib |
| Official title | Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B, Whole Cell Pertussis, Tetanus, Haemophilus Influenzae Type b, Diphtheria |
| Intervention type | Biological |
| Interventions | DTPw-HBV/Hib Kft vaccine GSK323527A, Tritanrix™-HepB/Hiberix™ |
| Enrollment | 148 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jun 1, 2006 |
| Last update posted | Sep 28, 2016 |
| Countries | Argentina, Nicaragua |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: